European equities traded in the US as American depositary receipts were relatively flat Friday morning, edging 0.01% lower to 1,453.06 on the S&P Europe Select ADR Index, which ended the week up 1.4% and closed out the month nearly 4% higher.
From continental Europe, the gainers were led by accommodations booking company trivago (TRVG) and software firm SAP (SAP), which rose 2.4% and 1.7% respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company Genfit (GNFT), which were up 1.2% and 0.9% respectively.
The decliners from continental Europe were led by pharmaceutical company Sanofi (SNY) and biotech firm BioNTech (BNTX), which fell 5.1% and 4.9% respectively. They were followed by telecommunications company Nokia (NOK) and semiconductor company Sequans Communications (SQNS), which lost 2.3% and 2.2% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Verona Pharma (VRNA) and pharmaceutical company GSK (GSK), which increased 2.6% and 2.3% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and utilities company National Grid (NGG), which advanced 1.9% and 1% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies Bicycle Therapeutics (BCYC) and NuCana (NCNA), which dropped 3.8% and 3% respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and biotech firm Autolus Therapeutics (AUTL), which were down 2.9% and 2.3% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.